Yescarta goes to China as Fosun Kite nabs historic first CAR-T OK
The CAR-T era has officially arrived in China.
Kite Pharma — which had lost out to Novartis in the battle for first FDA approval by just two months — can now claim a historic first at the National Medical Products Administration, where its joint venture with Fosun steered Yescarta to a landmark OK.
First accepted for priority review last March, the CD19-targeting therapy is indicated for patients with relapsed or refractory large B-cell lymphoma who have received two or more lines of prior treatment, according to an NPMA statement. That includes diffuse large B-cell lymphoma and primary mediastinal large B cell lymphoma, among others, they added.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.